Introduction/Background Many studies have focused on investigating the potential association between chemokine genetic variations and cancer susceptibility. The CXC chemokine ligand 12 (CXCL12) gene is increasingly being studied in cancer. The rs1801157 polymorphism involves the substitution of guanine with adenine at base pair 801 of the 3′-UTR of the CXCL12 gene. Our study examined the association of the rs1801157 polymorphism with uterine cancers.

Methodology A meta-analysis of case-controls studies was performed to investigate the association between CXCL12 polymorphism with uterine cancers.

Results Four publications on genetic polymorphisms met our inclusion criteria (three studies on cervical cancer and one study on endometrial cancer). Meta-analysis demonstrated a significant association between the CXCL12 G801A polymorphism and uterine cancers according to allelic G versus A (OR = 0.758, 95% CI = 0.632–0.909, p = 0.003), dominant GG + GA versus AA (OR = 0.473, 95% CI = 0.265–0.844, p = 0.011), recessive GG versus GA+AA (OR = 0.789, 95% CI = 0.655–0.952, p = 0.013), codominant GG versus AA (OR = 0.448, 95% CI = 0.247–0.813, p = 0.008), and codominant GA versus AA (OR = 0.530, 95% CI = 0.309–0.911, p = 0.022) random-models, indicating that the G allele, and GG or GA genotypes may represent a protective allele and genotypes against uterine cancers. Heterogeneity is lower (I2 ≤ 50%). Egger and Begg’s p-values were generally not significant (two-tailed p-value > 0.05), indicating the absence of the sample size effect for all genetic models of uterine cancers except for dominant, codominant models. There was no evidence of publication bias.

Conclusion Our results clearly reveal that the CXCL12 rs1801157 G/C polymorphism is associated with uterine cancers.

Disclosures The authors certify that there is no conflict of interest to declare.